Provided by Tiger Trade Technology Pte. Ltd.

ASCENTAGE-B

52.050
+0.0500.10%
Volume:3.80M
Turnover:197.09M
Market Cap:19.41B
PE:-13.10
High:53.150
Open:52.000
Low:50.800
Close:52.000
52wk High:95.350
52wk Low:31.350
Shares:373.00M
HK Float Shares:373.00M
Volume Ratio:1.17
T/O Rate:1.02%
Dividend:- -
Dividend Rate:- -
EPS(LYR):-3.972
ROE:-154.56%
ROA:-23.02%
PB:12.88
PE(LYR):-13.10
PS:29.71

Loading ...

Ascentage Pharma Appoints Dr. Debra Yu to Nomination Committee and Dr. David Sidransky as Lead Independent Director

Reuters
·
Dec 30, 2025

Assessing Ascentage Pharma (SEHK:6855) Valuation After New ASH 2025 Hematology Data on Olverembatinib and Lisaftoclax

Simply Wall St.
·
Dec 21, 2025

Ascentage Pharma to Present at J.P. Morgan Healthcare Conference

Reuters
·
Dec 17, 2025

CICC Maintains "Outperform" Rating on ASCENTAGE-B (06855) as POLARIS-1 Gains Approval in US and EU

Stock News
·
Dec 17, 2025

Is Ascentage Pharma Group International Pricing In Too Much Biotech Optimism After Big 3 Year Rally?

Simply Wall St.
·
Dec 14, 2025

Ascentage Pharma Reports Promising Second-Line CML Results for Olverembatinib at ASH 2025

Reuters
·
Dec 09, 2025

Ascentage Pharma Reports Strong Phase II Results for Lisaftoclax in BTK-Refractory CLL/SLL

Reuters
·
Dec 08, 2025

Revisiting Ascentage Pharma Group International (SEHK:6855)’s Valuation After Its Strong One-Year Share Price Gain

Simply Wall St.
·
Dec 07, 2025

BUZZ-Ascentage rises on progress of olverembatinib for blood cancer treatment

Reuters
·
Dec 05, 2025

HK Stock Movement | ASCENTAGE-B (06855) Rises Over 6% as POLARIS-1 Study for Olverembatinib (Nerlynx®) Gains FDA and EMA Approval

Stock News
·
Dec 05, 2025

ASCENTAGE PHARMA-B (06855) Receives FDA and EMA Approval for Global Phase III Trial of Olverembatinib (Nerlynx®) in First-Line Treatment of Ph+ ALL

Stock News
·
Dec 05, 2025

Ascentage Pharma (6855) Announces Global Phase III Study Clearance for Olverembatinib in First-Line Ph+ ALL

Bulletin Express
·
Dec 05, 2025

Ascentage Pharma Group International - Global Registrational Phase Iii Study of Olverembatinib Cleared by FDA and Ema

THOMSON REUTERS
·
Dec 05, 2025

Ascentage Pharma Wins FDA and EMA Clearance for Global Phase III Study of Olverembatinib in Ph+ ALL

Reuters
·
Dec 05, 2025

Ascentage Pharma (06855) Discloses November Share Capital and Equity Movements

Bulletin Express
·
Dec 04, 2025

10th Zhitong Capital Market Annual Conference Honors Excellence with 25 Awards Unveiled

Stock News
·
Dec 03, 2025

ASCENTAGE PHARMA GROUP-B (06855) Grants 1.3045 Million Restricted Share Units and 736,600 Share Options

Stock News
·
Nov 27, 2025

Ascentage Pharma (6855) Announces Additional RSU and Share Option Grants

Bulletin Express
·
Nov 27, 2025

Assessing Ascentage Pharma (SEHK:6855) Valuation Following Major Data Publication on Olverembatinib in Rare GIST Subtype

Simply Wall St.
·
Nov 27, 2025

Hong Kong Stock: ASCENTAGE-B Rises Over 3%

Deep News
·
Nov 26, 2025